Dermatomyositis & Polymyositis: IFN-α, Muscle NF-κB, MDA5 and Microbiome | INTI Belgium

⚠️ Direct Answer — Dermatomyositis/Polymyositis & Ginger:
Dermatomyositis (DM) and polymyositis (PM) are idiopathic inflammatory myopathies (IIMs) characterized by a type I IFN-α signature — plasmacytoid DCs (pDC) activated by RNA helicase MDA5 (anti-MDA5+ → severe interstitial lung disease) → IFN-α → muscle NF-κB → myocyte necrosis/apoptosis. Autoantibodies (anti-Jo-1, anti-Mi-2, anti-TIF1γ) reflect different phenotypes. 6-gingerol inhibits muscle NF-κB, reduces the IFN-α signature (NF-κB → IRF3/IRF7 ↓), and modulates the microbiome (Prevotella copri — correlated with flares in certain IIMs). INTI Elixir: 1.19g sugar per 100ml — vs GIMBER 35g sugar, which feeds Prevotella and activates muscle NF-κB. ⚠️ Never stop methotrexate, azathioprine, IVIG, or rituximab without consulting a rheumatologist. Regular CPK monitoring is essential.

Dermatomyositis/Polymyositis: IFN-α and muscle NF-κB mechanisms

IIMs affect ~3-10 people/100,000 (Belgium: ~2,000-5,000 patients). Mechanisms:

  • Type I IFN-α signature: Autoimmune RNA antigens → pDC → massive IFN-α → STAT1/STAT2 → IFN-stimulated genes (ISGs) → overexpression in muscle (DM biopsy) → myocyte necrosis. DM has the strongest IFN-α signature among IIMs. MDA5 (anti-CADM-140) → amyopathic DM + rapidly progressive interstitial lung disease (30-50% mortality without aggressive treatment).
  • Muscle NF-κB: NF-κB activation in myocytes → muscle TNF-α/IL-1β/IL-6 → myogenic atrophy (MyoD, myogenin ↓ → altered muscle differentiation) → proximal weakness. NF-κB → MuRF1/MAFbx ubiquitin ligases → muscle proteolysis.
  • Microbiome and IIMs: Prevotella copri is overrepresented in some forms of PM/DM — correlated with flares and myositis severity (ARTHRITIS 2019 study). Akkermansia muciniphila ↓ in severe forms. Ginger (Prevotella ↓, Akkermansia ↑) can modulate this profile.
  • Calcinosis: DM complication (especially juvenile DM) — calcium deposits in the skin/muscles via NF-κB → BMP-2 → ectopic osteoblasts. Anti-inflammatory agents (including ginger, NF-κB ↓) can slow calcinosis.
  • DM-associated neoplasia: Anti-TIF1γ+ (DM) is strongly associated with cancers (breast, ovarian, lung, colon) — systematic oncological screening is imperative.

6-Gingerol & Inflammatory Myopathy

IIM Target Ginger action Myositis impact
Muscle NF-κB 6-gingerol → myocyte IKKβ ↓ Muscle TNF-α/IL-1β ↓, CPK ↓
IFN-α signature (IRF3/IRF7) NF-κB ↓ → IRF3 activation ↓ ISG expression ↓, pDC ↓
Prevotella copri microbiome Polyphenols → Prevotella ↓ IIM flares correlated ↓
Muscle atrophy (MuRF1) NF-κB ↓ → MuRF1 ↓ → proteolysis ↓ Muscle strength preserved
Calcinosis (BMP-2) NF-κB ↓ → BMP-2 ↓ Calcinosis slowed
⚠️ CRITICAL MEDICAL WARNING — Dermatomyositis/Polymyositis:
  • Anti-MDA5+ DM — Medical emergency. Rapidly progressive interstitial lung disease (30-50% mortality without treatment). Emergency rituximab + tacrolimus + IV corticosteroids. Ginger is an adjuvant ONLY after stabilization.
  • Immunosuppressants (methotrexate, azathioprine, mycophenolate) — Never stop without a rheumatologist. Ginger: no documented interactions but inform your doctor.
  • IVIG (intravenous immunoglobulins) — Refractory DM treatment. Ginger: no interaction.
  • Rituximab — Anti-CD20 (anti-Mi-2+ DM, refractory PM). Ginger (mild immunomodulator) does not contraindicate rituximab. Validate with your rheumatologist.
  • Elevated CPK — Marker of IIM activity. If CPK >10x normal → suspicion of active IIM → urgent rheumatology consultation. Ginger (muscle anti-NF-κB) may contribute to CPK reduction in remission.
  • Anti-TIF1γ+ neoplasia — Systematic oncological screening. Ginger (anticancer via NF-κB ↓) can be an adjuvant in the oncological context of paraneoplastic DM — never a substitute for oncological follow-up.

INTI vs GIMBER — Dermatomyositis/Polymyositis

IIM Criterion INTI Elixir GIMBER
Sugar (Prevotella + NF-κB) 1.19g/100ml ~35g → Prevotella fuel + muscle NF-κB ↑
IFN-α signature NF-κB ↓ → IRF3 ↓ → IFN-α ↓ Sugar → NF-κB ↑ → IFN-α amplified
CPK (activity) 6-gingerol → muscle NF-κB ↓ → CPK ↓ Sugar → anti-inflammatory-science-utilisation">natural anti-inflammatory → CPK ↑
Akkermansia/microbiome Polyphenols → Akkermansia ↑, Prevotella ↓ Sugar → Prevotella ↑
FAQ — Dermatomyositis/Polymyositis & Ginger (8 questions)

Q1: Can ginger reduce CPK in myositis?
Via muscle NF-κB ↓ → MuRF1 ↓ → muscle proteolysis ↓ → CPK. No randomized clinical trials for IIM/ginger. As an adjuvant to medical treatment (MTX, AZA, IVIG), INTI may contribute to activity reduction.

Q2: What is the IFN-α signature in DM and why is it important?
The type I IFN-α signature (overexpression of ISGs in muscle and blood cells) is almost pathognomonic for DM. It is measurable by blood IFN-α score (ISG15, IFIT1, MX1). Its reduction is a biomarker of therapeutic response. Ginger (NF-κB ↓ → IRF3/IRF7 ↓) can reduce it in vitro.

Q3: Anti-MDA5 positive — what's the urgency?
Anti-MDA5+ DM → risk of rapidly progressive interstitial lung disease (30-50% mortality in 6 months). ICU/pulmonology emergency: IV methylprednisolone + rituximab or tacrolimus + IVIG. Ginger is an adjuvant AFTER stabilization, never a substitute for this emergency.

Q4: Calcinosis — can ginger help?
Calcinosis (especially juvenile DM) involves NF-κB → BMP-2 → ectopic osteoblasts → calcium deposits. Ginger (NF-κB ↓ → BMP-2 ↓) is theoretically beneficial for slowing calcinosis. It complements validated treatments (colchicine, IVIG, diltiazem).

Q5: Anti-TIF1γ+ and neoplastic risk — what role for ginger?
Anti-TIF1γ+ DM is strongly associated with cancers (breast, ovarian, lung). Ginger (NF-κB ↓ → tumor cell apoptosis ↑, NRF2 ↑ → carcinogen detoxification) can be an adjuvant in the oncological context of paraneoplastic DM. Systematic oncological screening is a priority.

Q6: DM vs PM — how does ginger act differently?
DM (predominant pDC/IFN-α): ginger inhibits IFN-α via NF-κB/IRF3 ↓. PM (predominant cytotoxic T cells/perforin): ginger anti-muscle NF-κB → TNF-α ↓. In both cases, the microbiome axis (Prevotella ↓) is relevant.

Q7: DM dysphagia — how to use INTI?
Oropharyngeal dysphagia is common in DM/PM (pharyngeal myositis). INTI diluted in water is a liquid — evaluate consistency with the speech therapist. For severe dysphagia: INTI administered after speech-language evaluation.

Q8: Where to find INTI in Belgium for inflammatory myositis?
INTI is available on inti-drink.com and in Belgian pharmacies/health stores. 1.19g sugar, no alcohol — a suitable profile for DM/PM patients on immunosuppression.

💪 INTI vs GIMBER — Dermatomyositis/Polymyositis

GIMBER: 35g sugar → Prevotella fuel + muscle NF-κB ↑ + amplified IFN-α
INTI: 1.19g sugar → Prevotella ↓ + muscle NF-κB ↓ + IRF3 ↓ → IFN-α signature ↓

⚠️ Anti-MDA5+: MEDICAL EMERGENCY — Never delay care

Discover INTI — 1.19g sugar

Related articles

To learn more, also read:

Useful INTI pages

To go further:

Back to blog